A 28.8-day half-life is doing a lot of work in this story. That single pharmacokinetic figure is what allows Infex Therapeutics to design a quarterly dosing regimen for RESP-X — and quarterly dosing, in a chronic disease requiring indefinite treatment, is the difference between a therapy patients actually maintain and one they abandon. The Phase IIa data presented at ATS 2026 show that this antibody behaves in diseased lung tissue almost exactly as it did in healthy volunteers, which is not a given when you move from Phase I to a patient population with structurally abnormal airways and chronic infection.
The trial’s most clinically consequential finding isn’t the safety read — clean tolerability with no infusion reactions across both dose cohorts was expected for a humanized IgG4 — it’s the target coverage data. Every Pseudomonas aeruginosa isolate pulled from patient sputum encoded PcrV, the T3SS protein RESP-X is designed to block, and every sequence bound the antibody. That’s 100% target prevalence in a real-world Pa-colonized NCFB population, which eliminates the companion diagnostic problem that could otherwise complicate enrollment design in a Phase IIb. Bronchoalveolar lavage confirmed drug reached epithelial lining fluid at 48 hours post-dose, answering the lung-penetration question that trips up many systemic antibodies targeting respiratory pathogens.
The efficacy signal is exploratory and the p-value of 0.08 is not a clean result, but it’s directionally meaningful in a Phase IIa study not powered to detect a statistically significant exacerbation reduction. The comparison — fewer exacerbations from day 1 to day 180 versus the prior 12 months — is a within-patient historical control, which inflates the signal somewhat, but in a disease where exacerbation frequency worsens over time, any reduction against a patient’s own trajectory is worth taking seriously. No anti-drug antibodies were detected at any timepoint, removing one of the more plausible failure modes for a long-cycle dosing regimen.
Infex now heads into regulatory conversations to define the Phase IIb design. The marker that matters: whether regulators accept exacerbation rate reduction as a primary endpoint or push toward a harder outcome like time-to-first hospitalization. That endpoint negotiation will determine trial size, duration, and ultimately whether RESP-X can reach a population that currently has no approved preventative therapy.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
